TY - JOUR
T1 - Temporal Change in Tumor Volume Following Stereotactic Radiosurgery to a Single Brain Metastasis
AU - Goethe, Eric A.
AU - Rao, Ganesh
AU - Harvey, Adrian
AU - Mesfin, Fassil B.
AU - Li, Miao
AU - Mahajan, Anita
AU - Ye, Jiabu
AU - Suki, Dima
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/4
Y1 - 2020/4
N2 - Background: Stereotactic radiosurgery (SRS) can be used to achieve local control of metastatic brain lesions. However, the temporal response of these lesions to SRS is incompletely understood and quantified. We aimed to examine the temporal response to SRS of single brain metastases from 4 different primary cancers. Methods: A retrospective chart review was performed of patients who underwent SRS at our institution from 2009 to 2012. Clinical, treatment, and volumetric data were collected. All patients were treated according to Radiation Therapy Oncology Group 90-05 schema. Results: This study included 204 patients (116 men and 88 women) with a median age of 61 years (range, 27–86 years). Of patients, 20 (10%) had breast cancer, 79 (39%) had non–small cell lung cancer, 69 (34%) had melanoma, and 36 (17%) had renal cell carcinoma. Initial overall median tumor volume was 0.8 cm3 (range, 0.02–16.9 cm3). Median tumor volume was 0.5 cm3 (range, 0.02–20.4 cm3) at 1 month after SRS, 0.3 cm3 (range, 0.02–10.8 cm3) at 3 months after SRS, and 0.4 cm3 (range, 0.02–18.6 cm3) at 6 months after SRS. Based on the joint model constructed from our results, we demonstrate a median 16% (95% confidence interval, 11%–20%) reduction in tumor volume every 30 days. Conclusions: The results of this study demonstrate a consistent reduction in tumor volume following SRS over a 6-month period. Responses were modest over the first 30 days but accelerated at 3 months and varied by tumor type.
AB - Background: Stereotactic radiosurgery (SRS) can be used to achieve local control of metastatic brain lesions. However, the temporal response of these lesions to SRS is incompletely understood and quantified. We aimed to examine the temporal response to SRS of single brain metastases from 4 different primary cancers. Methods: A retrospective chart review was performed of patients who underwent SRS at our institution from 2009 to 2012. Clinical, treatment, and volumetric data were collected. All patients were treated according to Radiation Therapy Oncology Group 90-05 schema. Results: This study included 204 patients (116 men and 88 women) with a median age of 61 years (range, 27–86 years). Of patients, 20 (10%) had breast cancer, 79 (39%) had non–small cell lung cancer, 69 (34%) had melanoma, and 36 (17%) had renal cell carcinoma. Initial overall median tumor volume was 0.8 cm3 (range, 0.02–16.9 cm3). Median tumor volume was 0.5 cm3 (range, 0.02–20.4 cm3) at 1 month after SRS, 0.3 cm3 (range, 0.02–10.8 cm3) at 3 months after SRS, and 0.4 cm3 (range, 0.02–18.6 cm3) at 6 months after SRS. Based on the joint model constructed from our results, we demonstrate a median 16% (95% confidence interval, 11%–20%) reduction in tumor volume every 30 days. Conclusions: The results of this study demonstrate a consistent reduction in tumor volume following SRS over a 6-month period. Responses were modest over the first 30 days but accelerated at 3 months and varied by tumor type.
KW - Metastatic brain disease
KW - Stereotactic radiosurgery
KW - Volumetric response
UR - http://www.scopus.com/inward/record.url?scp=85078763157&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078763157&partnerID=8YFLogxK
U2 - 10.1016/j.wneu.2019.12.168
DO - 10.1016/j.wneu.2019.12.168
M3 - Article
C2 - 31917308
AN - SCOPUS:85078763157
SN - 1878-8750
VL - 136
SP - e328-e333
JO - World Neurosurgery
JF - World Neurosurgery
ER -